Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution
Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.
FEP is used to predict how strongly drug candidates bind to their targets, helping guide compound selection. However, despite its recognised accuracy, adoption has often been limited by computational cost, usability barriers and challenges in modeling complex chemical transformations.
Here's some exciting news about the Cambridge Stock Exchange Project (CSEP).
The Cambridge Stock Exchange Project is creating a platform for accessing liquidity from the market inside high-density innovation ecosystems across the UK.
You can also learn more about the initiative on the Cambridge Stock Exchange Project website.
About the role:
The Director, Clinical Paediatric and Rare Oncology is a senior clinical leader responsible for shaping and delivering LifeArc’s clinical strategy in paediatric and adult rare oncology, aligned to LifeArc’s organisational mission and priorities.
We’re looking for a technically capable and reliable Senior/Research Scientist to join our Discovery Team at Sortera Bio. This is a lab-based role focused on the operation of our proprietary Deep Screening technology, and provision of broader support for library preparation, NGS, and hit validation workflows.
At Insmed, every moment and every patient counts — and so does every person who joins in. As a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases, you’ll be part of a community that prioritizes the human experience, celebrates curiosity, and values every person’s contributions to meaningful progress. That commitment has earned us recognition as Science magazine’s No.
Transitioning from preclinical development into first-in-human is one of the most critical and complex stages in drug development. Early strategic decisions can have a significant impact on timelines, regulatory interactions, study success, and overall programme progression.
Join Dr Jon Sisson, Executive Medical Director, Clinical Development and Regulatory Strategy, and Christopher Floyd, SVP, Head of Clinical and Medical and Head of Neuroscience, as they answer your questions and share practical insights on the key considerations for successful early clinical development.
About the Wellcome Genome Campus
WGCL is the owner, operator and developer of the Wellcome Genome Campus, which is located nine miles south of Cambridge, within an established life science cluster and ecosystem. WGCL and the Campus are owned by a world-renowned endowment fund that is committed to expanding its existing campus into a global centre for genomics, biodata sciences and associated technologies.
By Tony Jones, CEO, One Nucleus - Email: [email protected]
